Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
astatine (211At) substance P
- Development stage
- Unknown
- Lead developer
- ACCELERATE.EU
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intratumoral, Intralesional
01
Overview
211At-SubP is a targeted alpha-particle therapy (TAT) radiopharmaceutical consisting of the neuropeptide Substance P labeled with the alpha-emitting radioisotope astatine-211. Developed by the ACCELERATE.EU consortium, the compound is designed to treat glioblastoma multiforme (GBM) by targeting the neurokinin-1 receptor (NK1R), which is highly expressed on the surface of glioma cells but has limited expression in healthy brain tissue. Upon binding to NK1R, the astatine-211 isotope delivers high-linear energy transfer (LET) alpha radiation over a very short range (50-100 μm), causing lethal double-strand DNA breaks in the tumor cells while sparing adjacent healthy neurons. The drug is typically administered via local injection into the tumor or the post-operative resection cavity to bypass the blood-brain barrier and maximize local dose intensity.
- Other names
- astatine-211-labeled Substance Pastatine211-labeled Substance Pastatine 211-labeled Substance P[211At]At-Substance P211At-SP211At-SubP compound
02
Targets
TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on astatine (211At) substance P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on astatine (211At) substance P.